KR20150040068A - A pharmaceutical comprising eclipta prostrata for treating of preventing colitis - Google Patents

Abstract

The present invention relates to a composition containing Eclipta prostrate as an active ingredient for preventing, alleviating, or treating cellular inflammation and colitis. The composition according to the present invention retains effects of inhibiting the weight loss and disease activity, inhibiting the reduction of the large intestine length, and reducing the expression PGE_2 (Prostagladin) and COX-2, thereby retaining an effect of preventing, alleviating, or treating colitis.

Description

TECHNICAL FIELD The present invention relates to a composition for preventing, ameliorating or treating colitis, which contains an extract of Angelica keiskei koidz. As an active ingredient.

The present invention relates to an Eclipta The present invention relates to a composition for preventing, ameliorating or treating colitis, which contains, as an active ingredient, prostrata .

The composition according to the present invention has the effect of inhibiting weight loss and disease activity, inhibiting the decrease of the colon length and reducing the expression of PGE ₂ (Prostagladin) and COX-2, thereby preventing and improving colitis ≪ RTI ID = 0.0 > and / or < / RTI >

The composition according to the present invention has a technical feature that the concentration of the extract of the myrrhylose extract contained as an active ingredient is 500 mg / kg on the basis of administration once a day at 4 weeks of the mouse.

Colitis is a term that is widely used to refer to inflammatory diseases of unknown etiology that occur in the digestive tract. Ulcerative colitis is a typical colitis.

Ulcerative colitis usually occurs in the sigmoid colon and rectum of the left side of the colon. It may also occur in the ileum, often at the end of the small intestine associated with the large intestine.

It is characterized by inflammation and ulceration in the mucosa inside the colon composed of the colon and the rectum. The main symptoms are hemorrhagic diarrhea, abdominal pain, and urgency of the stool. In severe cases, It defecates several times a day and suffers from dehydration, anemia, fever and weight loss.

The etiology of ulcerative colitis is not known, but it is presumed to be caused by psychological factors, environmental factors such as smoking / dieting, or physical and genetic factors of each patient. It has been recognized as a disease with low frequency of incidence in Korea because of frequent incidence in western countries such as Europe or USA. Recently, incidence of incidence has been increasing according to westernization of domestic dietary habits.

However, since pathologic - physiological findings of colitis have not been elucidated, effective therapy is in short supply.

Currently used ulcerative colitis therapies are pharmacologic and surgical treatment.

Drugs used for pharmacological treatment include aminosalicylate preparations such as sulfasalazine and mesalazine, steroid preparations, and infliximab, which do not respond to steroid therapy Immunosuppressants such as azathioprine, 6-mercaptopurine and cyclosporin, corticosteroids such as prednisone and the like have been used.

However, serious side effects such as skin rash, fever, pancreatitis, hepatitis, hemolytic anemia, and bone marrow suppression due to hypersensitivity as well as nausea, vomiting, poor digestion, anorexia and headache may result when these drugs are administered for a long period.

For example, mesalazine, which is the most widely used for ulcerative colitis, has a high rate of absorption into the fetus through the placenta even at low concentrations, and its use in pregnant women is limited. Systemic hypersensitivity and interstitial nephritis are reported as side effects, Corticosteroids are useful for short-term relief therapy, but they are used only for short-term therapy because of severe side effects during systemic use.

In addition, these drugs are drugs that are used as a temporary measure rather than a drug targeted for the pathogenesis of colitis, and can not cure colitis.

Surgical treatment techniques include colonic resection, but adverse effects such as bladder pain, night fecal incontinence, and decreased fertility in women have been reported.

Therefore, there is an urgent need to find new colchicine treatment substances having high efficacy and safety.

The present inventors intend to develop a composition for prevention and treatment of cell inflammation and colitis by using Hansik-suk, and a brief description will be given thereof.

Eclipta prostrata ) is an annual herbaceous herbaceous plant distributed in Jeju Island and the southern part of Gyeonggi Province. It contains saponin, tannin, ecliptin, vitamin A and nicotine. The taste is sweet and temperate, and there are no side effects even when taken with other medicines.

It is used for medicinal purposes in all areas including flowers, and has the effect of acting on hemostasis, muscle and bone strengthening, and the effect of diphtheria, back pain, dysentery, uterine inflammation, darkening of hair and hair.

In the meantime, a brief review of previous studies related to Hansuksu has revealed that Hanshikosho has anti-inflammatory effects, but the effect of Hansuksuo on colitis has not been studied.

In addition, Korean Patent Registration No. 10-1060308 discloses a composition for treating diabetes using sun-dried salt and a extract of a herb medicine. Korean Patent Laid-Open Publication No. 10-2012-0052894 discloses a composition for treating diabetes mellitus, Korean Patent Registration No. 10-1312965 discloses a composition for enhancing elasticity and improving wrinkles using an onion, a comfrey, a herbicide and a cacao extract. .

That is, conventional studies and prior patents have not been studied for colitis.

In order to demonstrate the efficacy of the treatment of H. pylori against each symptom of colitis, the present inventors prepared a mouse model inducing colitis, measured weight loss inhibitory efficacy and disease activity, extracted colonic tissues, And COX-2, respectively.

Korean Registered Patent No. 10-1060308 (2011, 08, 23) Korean Patent Laid-Open Publication No. 10-2012-0052894 (2012, 05, 24) Korean Patent Publication No. 10-1312965 (2013, 09, 17)

Joey window. Anti - Inflammatory Effect of. Doctoral thesis. Graduate School of Daegu Haany University. 2009, 12

It is an object of the present invention to provide a composition for preventing, ameliorating or treating colitis, comprising as an active ingredient an extract of myrtle.

It is an object of the present invention to provide a method of preventing, ameliorating, or treating colitis with efficacy that inhibits weight loss and disease activity, inhibits the reduction of colon length, and reduces the expression of PGE ₂ (Prostagladin) and COX-2 And to provide a composition for such a composition.

It is an object of the present invention to provide a composition for preventing, improving or treating a disease characterized in that the concentration of the moxa extract contained as an active ingredient is 500 mg / kg on a once-a-day administration basis at 4 weeks of age .

It is an object of the present invention to provide a health functional food for preventing or ameliorating a colitis containing an extract of myrrh.

It is an object of the present invention to provide a pharmaceutical preparation for preventing, ameliorating or treating colitis, comprising an extract of Trichoderma sp. As an active ingredient.

The present invention aims at solving the technical problem by providing a composition for prevention, improvement or treatment of colitis including an extract of myrrh.

The present invention relates to a pharmaceutical composition comprising a moxa extract as an active ingredient, an effect of inhibiting weight loss and disease activity, an effect of inhibiting reduction of the colon length, and an effect of reducing the expression of PGE ₂ (Prostagladin) and COX-2 And to provide a composition for preventive treatment.

The present invention aims to solve the technical problem by providing a composition for preventing, ameliorating or treating colitis which is 500 mg / kg on the basis of once-a-day administration once a day, at 4 weeks of age, the concentration of the extract of the marshmallow, as an active ingredient.

The composition according to the present invention has the effect of inhibiting weight loss and disease activity, inhibiting the decrease of the colon length, and reducing the expression of PGE ₂ (Prostagladin) and COX-2, thereby preventing, improving or treating colitis .

The composition according to the present invention has the effect of establishing a new use of Hansiksuccho which is mainly used only as a composition for treatment of dermatitis or hair dyeing.

FIG. 1 is a graph comparing the body weights of the control group, the DSS-administered group, the EP-treated group, and the SFZ-treated group.
FIG. 2 is a graph comparing disease activity scores of the control group, the DSS administration group, the EP administration group, and the SFZ administration group.
FIG. 3 is a photograph showing a comparison of the colon lengths of the control group, the DSS-administered group, the EP-treated group and the SFZ-treated group.
4 is a graph comparing the colon lengths of the control, DSS, EP, and SFZ administration groups.
FIG. 5 is a graph comparing the amounts of PGE ₂ expression in the control, DSS, EP, and SFZ administration groups.
FIG. 6 is a photograph showing the amount of COX-2 expression in the control, DSS, EP, and SFZ administration groups.

The terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms and the inventor may properly define the concept of the term in order to best describe its invention It should be construed as meaning and concept consistent with the technical idea of the present invention.

Therefore, the embodiments, reference examples, experimental examples, production examples, and drawings described in the present specification are merely the most preferred examples of the present invention and do not represent all the technical ideas of the present invention. Therefore, It should be understood that various equivalents and modifications may be substituted for those embodiments.

Example  1. Preparation of the extract

The composition according to the present invention is for preventing, ameliorating or treating colitis, and contains an extract of the myrtle plant as an active ingredient.

1) It extracts Hansikucho.

Depending on the design conditions, various extraction methods such as solvent extraction, carbon dioxide supercritical extraction, steam distillation, microwave process extraction, hot water extraction, percolation extraction and fermentation extraction can be used as extraction methods.

In addition, one or more extraction methods can be used to extract the first order or more.

Extraction solvents during the solvent extraction process Various solvents may also be used. Extractable solvents include water, ethanol, methanol, fatty oils, glycerin, mayo, flouroprene glycol, ether, chloroform, petroleum ether, hexane, benzene, methylene chloride, ethyl acetate, acetone, butanol and isopropanol. Preferably, water is used, but not limited thereto.

In addition, two or more solvents having different distribution coefficients may be simultaneously used, or two or more solvents may be used to extract a second or more solvent.

The amount and concentration of the extraction solvent can also be adjusted depending on the type of the solvent, and the weight ratio of the extraction solvent and the concentration of the solvent can be variously set. Preferably, the weight ratio of the extracting solvent 10: Hansikoshi 1, but the present invention is not limited thereto.

Bacteria and fungi at the time of performing the fermentation extraction method may also be various bacteria. Bacteria and fungi that can be used include Hwanggukjun, Bacillus, and lactic acid bacteria.

The extraction time and the temperature at the time of extraction may also vary depending on the design conditions. It may be less than 12 hours, or more than 12 hours. It can be more than one day.

Depending on the design conditions, it is also possible to extract fractions of fractions. Water or ethanol extracts can be fractionated into a water layer and a hexane layer by adding distilled water followed by hexane. Ethyl acetate may be further added to the water layer to separate the ethyl acetate layer and the water layer, and the butanol layer and the water layer may be finally added to the water layer.

In addition, distilled water may be added to the methanol extract of Hansuksikcho, and hexane may be added to separate the water layer and the hexane layer. Ethyl acetate may be further added to the water layer to separate the ethyl acetate layer and the water layer, and the butanol layer and the water layer may be finally added to the water layer.

In addition, distilled water may be added to the C ₁ -C ₅ aliphatic alcohol extract of Hansuk Ecstasy, and then hexane may be added to separate the water layer and the hexane layer. Ethyl acetate may be further added to the water layer to separate the ethyl acetate layer and the water layer, and the butanol layer and the water layer may be finally added to the water layer.

Filtration, concentration, and the like may be performed before and after the extraction.

The filtration method may be selected from the group consisting of atmospheric pressure filtration, gravity filtration, centrifugal filtration, vacuum filtration, pressure filtration, pressure filtration, etc., and the concentration method may be selected from freeze concentration, vacuum concentration and evaporation concentration.

2) Dry the extract.

For the drying method, various drying methods such as a positive drying method, a negative drying method, a freeze drying method, and a hot air drying method may be used, and the freeze drying method may be preferably used, but is not limited thereto.

Depending on the design conditions, a further grinding process may be carried out. The pulverization method can also be selected from various methods such as dry pulverization.

As an example of the final process, 100 g of Hansencho is heated by 1 L of water for 3 hours to extract hot water, and then the obtained Hanssikhiko water extract can be lyophilized and pulverized, but the present invention is not limited thereto.

Example  2. Preparation of Health Functional Foods Containing Hanchuncho Extract as Active Ingredients

The health functional food according to the present invention is intended to prevent or ameliorate colitis, and contains an extract of myrrh.

1) A foodstuff acceptable food additive is added to the mushroom extract prepared by the process described in Example 1.

Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxy, hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The composition of the present invention can be variously used for foods and beverages for prevention or improvement of colitis. Examples of foods to which the composition of the present invention can be added include various foods, beverages, gums, tea, vitamin complexes, health supplements and the like, and they can be used in the form of powders, granules, tablets, have.

At this time, the amount of the composition in food or beverage is generally from 1 to 5% by weight of the total food weight of the health food composition of the present invention, and the health beverage composition contains 0.02 to 10 g, preferably 0.3 To 1 g.

The health beverage composition of the present invention contains, as an essential ingredient, the extract of Angelica keiskei L. as an essential ingredient in the indicated ratio, and there is no particular limitation to the liquid ingredient, and it may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages.

Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention can be applied to various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and aging agents (cheese, chocolate etc.), pectic acid and its salts, , Protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and vegetable beverages. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

Example  3. Preparation of Pharmaceutical Preparations Containing Hansikschae Extract as Active Ingredients

The pharmaceutical preparation according to the present invention is for prevention, improvement or treatment of colitis, and contains an extract of myrrh.

1) A pharmaceutical preparation is prepared by adding a pharmaceutically acceptable additive to the extract of the myrrh.

The composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions, Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxy, hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.

Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as calcium carbonate, sucrose, ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used.

Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included .

Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsion-freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.

As the base of the suppository, witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like can be used.

The preferred dosage of the composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. However, for the desired effect, it is preferable to administer 0.0001 mg / kg to 50 mg / kg per day.

The administration may be carried out once a day or several times. Accordingly, the dosage is not limited in any way to the scope of the present invention.

In addition, the composition of the present invention can be administered to mammals such as rats, mice, livestock, and humans in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.

Experimental Example  One. Extract Weight loss inhibition efficacy

In the beginning, it is revealed that all the experimental examples used the extract of the myrtle plant produced by the process of Preparation Example 1 and the animal model produced by the process of producing the animal model of colitis described in Experimental Example 1.

(1) Preparing the experiment

1) Production of colitis animal model

Dextran sulfate sodium (DSS) -induced colitis animal model is shown below.

BALB / c mouse female 4 weeks old (polyarthritis) was used for 1 week in an animal laboratory.

(EP, 500 mg / kg) and sulfasalazine (500 mg / kg) were administered to the experimental animals for 7 days. After the administration of 5% dextran sulfate sodium (molecular weight: 36,000-50,000) (SFZ, 100 mg / kg) was administered once daily for the duration of the study.

(2) Experimental process

Symptoms of weight loss appear at the onset of colitis. Therefore, the present study aimed to investigate the efficacy of the extract of Trichinella sp.

Experiments were performed by measuring and recording the body weight change rate of all subjects for 7 days.

(3) Experimental results

FIG. 1 is a graph comparing the body weights of the control group, the DSS-administered group, the EP-treated group, and the SFZ-treated group.

On the 7th day of the experiment, the final body weights of all subjects were approximately 100 g for the control group, 81 g for the DSS group, 87 g for the DSS + SFZ group, and 89 g for the DSS + EP group. The decrease in the DSS + SFZ group and the DSS + EP group was inhibited in the positive control group.

In the DSS-treated group, the body weight was decreased by about 19 g compared with the control group.

In particular, the DSS + EP group showed an increase of about 2g compared with the DSS + SFZ group, and the EP had higher weight loss inhibitory power than SFZ.

Thus, it can be concluded that the extract of Hansunikcho inhibits weight loss in a colitis-induced mouse model.

Experimental Example  2. Inhibitory effect of Hansik's extract on the disease activity

(1) Experimental process

The activity of the disease was quantified by quantifying the progress of the disease. In this experiment, the effect of the extract of the. Was investigated to inhibit the disease activity of colitis.

Experiments were carried out by measuring the disease activity from 0 to 4 according to the degree of weight loss, the stiffness of the stool, and the presence or absence of the stool.

The stool stiffness and the presence or absence of stool were classified according to the criteria described in [Table 1].

Longitude of feces Presence or absence of blood Normal Well-formed
Normal stool Negative There's blood around the rectum.
If not Loose stool It does not form a normal shape,
Loose positive When blood is visible around the anus Diarrehea Anal
Diarrhea Gross bleeding In a state of unclean blood
When buried around the anus

The disease activity was also calculated based on the criteria described in [Table 2] (weight score + stool score + stool score) / 3.

score Weight score (%) Stiffness score of stool Blood stain score 0 None Normal Negative One 1-5 Loose stool Negative 2 5 to 10 Loose stool Positive 3 10 to 15 Diarrehea Positive 4 > 15 Diarrehea Gross bleeding

(2) Experimental results

FIG. 2 is a graph comparing disease activity scores of the control group, the DSS administration group, the EP administration group, and the SFZ administration group.

The disease activity was estimated to be 0 for control, 2.5 for DSS, 1.8 for DSS + EP, and 1.75 for DSS + SFZ.

In the DSS-treated group, the disease activity was increased by about 2.5 compared to the control group, and it was confirmed that after the EP administration, the DSS-treated group was reduced by 0.7 compared with the DSS-treated group.

DSS-treated group had the highest disease activity, and DSS + SFZ treated group and DSS + EP treated group showed low disease activity.

Thus, it can be concluded that the extract is effective for inhibiting disease activity in a colitis-induced mouse model.

Experimental Example 3. Antioxidant Effect of Hansencho Extract

(1) Experimental process

In the case of colitis, the tissue is damaged and the length of the colon is reduced. Therefore, the present study was conducted to investigate the effect of the extract of Hansikoso extract on colon length reduction symptoms.

The experiment was carried out as follows.

Colitis model mice were anesthetized with diethyl ether for 7 days, then anesthetized mice were lavaged and blood was collected from the abdominal aorta and the colon was removed.

The length of the large intestine was measured from the cecum to the anus.

(2) Experimental results

FIG. 3 is a photograph showing a comparison of the colon lengths of the control group, the DSS-administered group, the EP-treated group and the SFZ-treated group.

4 is a graph comparing the colon lengths of the control, DSS, EP, and SFZ administration groups.

As a result of comparing the lengths of the colon, the average length of the control group was 7.25 cm, the DSS group was 4.9 cm, the DSS + EP group was 5.3 cm and the DSS + SFZ group was 6 cm.

In the DSS-treated group, the colon length was reduced by about 2.35 cm compared to the control group, and it was confirmed that after the administration of EP, the colon length was increased by about 0.4 compared with the DSS-administered group.

The length of the DSS-treated group was the shortest, and the length of the DSS + EP and DSS + SFZ treated groups was longer than that of the DSS treated group.

Thus, it can be concluded that the extract is effective in inhibiting the decrease of the length of the colon in a colitis-induced mouse model.

Experimental Example  4. In the colon tissues of the extract PGE ₂ Expression inhibition efficacy

(1) Experimental process

In the case of colitis, PGE ₂ is expressed in the colon tissue and PGE ₂ is metabolized from arachidonic acid and mediates the inflammatory reaction including fever.

In other words, inhibition of PGE2 is one of the main mechanisms in the treatment of colitis. Therefore, in this experiment, we investigated the efficacy of the extract of Phellinus L. pertussis in inhibiting the expression of PGE2 in colon tissues.

The experiment was carried out as follows.

Expression of PGE ₂ amount was measured using PGE ₂ EIA kit of ENZO Life Science (Life Sciences). 100 μl of the diluted tissue solution was loaded into a 96-well plate coated with a goat anti-mouse, and a primary antibody solution 50 And 50 μl of PGE ₂ conjugate were added at 4 ° C. overnight.

Substrate solution was treated with 200 μl each for 45 minutes, treated with 50 μl of stop solution and absorbance was measured at 450 nm. The value of each sample was divided by the quantified value and corrected.

(2) Experimental results

FIG. 5 is a photograph comparing the amounts of PGE ₂ expression in the control group, the DSS-administered group, the EP-treated group, and the SFZ-treated group.

The expression levels of PGE ₂ were approximately 210 ng / mL in control, 630 ng / mL in DSS, 400 ng / mL in DSS + EP and 270 ng / mL in DSS + EP.

The amount of PGE ₂ expression in the DSS-treated group was about 3-fold higher than that in the control group.

That is, in the DSS administration group, PGE ₂ In the DSS + SFZ and DSS + EP groups, PGE ₂ And the expression level was relatively lower than that of the DSS administration group.

Thus, it can be concluded that the extract of Hansunikcho has the effect of inhibiting the expression of PGE ₂ in the colonic tissues of the colitis-induced mouse model.

Experimental Example  5. In the colon tissues of the extract COX -2 expression inhibition efficacy

(1) Experimental process

COX-2 is expressed by inflammatory stimulation at the onset of colitis, and COX-2 is an enzyme that produces PGE ₂ and thromboxane described in Experimental Example 4. [

Thus, it is important to inhibit the expression of COX-2 in the same way as PGE _{2 in} the treatment of colitis. Therefore, in this experiment, we investigated the efficacy of the extract of Phellinus vulgaris as an inhibitor of PGE2 expression in colon tissues.

The experiment was carried out as follows.

Colon tissue was washed twice with ice-cold PBS and dissolved in an ice-cold protein extraction solution (Intron, Daejeon).

The cell lysate was centrifuged at 15,000 rpm for 15 minutes at 4 ° C. Then, the supernatant was mixed with 2 × SDS sample buffer in an equal volume, boiled at 5 ° C. for 5 minutes, and then separated into 10% SDS-PAGE gel.

After electrophoresis, the membrane was transferred to methylated PVDF membranes with electrophoretic transfer.

Membranes were blocked in 5% skim milk for 1 hour and primary antibodies were reacted overnight at 4 ° C in PBST containing 3% skim milk.

Membranes were washed five times with PBST and incubated with HRP-conjugated secondary antibodies for 1 hour.

After washing with PBST 5 times, the luminol agent (Luminol Reagent (Santa Cruz Biotechnology, CA, USA) was treated for 5 minutes and exposed to X-ray film.

(2) Experimental results

FIG. 6 is a photograph showing the amount of COX-2 expression in the control, DSS, EP, and SFZ administration groups.

As a result of comparing the expression level of COX-2, it was found that the COX-2 expression band was the most dense and vivid in the DSS administration group, and the band was greatly faded in the DSS + EP administration group.

That is, the expression level of COX-2 was the highest in the DSS-treated group and that in the DSS + EP treated group and the DSS + SFZ treated group was relatively lower than that of the DSS treated group.

Thus, it can be concluded that the extract of Hansunikcho has the effect of inhibiting the expression of COX-2 in the colonic tissues of the colitis-induced mouse model.

Claims (5)

A composition for preventing, ameliorating or treating colitis, which comprises an extract of Hanchunikcho as an active ingredient.
The method according to claim 1,
The extract is effective for inhibiting weight loss and disease activity, inhibiting the decrease of the colon length, and reducing the expression of PGE ₂ (Prostagladin) and COX-2 in the colon tissue Composition.
The method of claim 2,
Wherein the concentration of the extract is 500 mg / kg once-a-day on a 4-week-old mouse.
A health functional food for preventing or ameliorating a major salt to which the composition according to claim 1 is added with a pharmaceutically acceptable additive.
A pharmaceutical preparation for preventing, ameliorating or treating colitis with the addition of a pharmaceutically acceptable additive to the composition according to claim 1.

Images